• Aucun résultat trouvé

The lipoprotein lipase inhibitor ANGPTL3 is negatively regulated by thyroid hormone

N/A
N/A
Protected

Academic year: 2021

Partager "The lipoprotein lipase inhibitor ANGPTL3 is negatively regulated by thyroid hormone"

Copied!
8
0
0

Texte intégral

(1)

HAL Id: hal-02666173

https://hal.inrae.fr/hal-02666173

Submitted on 31 May 2020

HAL is a multi-disciplinary open access

archive for the deposit and dissemination of

sci-entific research documents, whether they are

pub-lished or not. The documents may come from

teaching and research institutions in France or

abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est

destinée au dépôt et à la diffusion de documents

scientifiques de niveau recherche, publiés ou non,

émanant des établissements d’enseignement et de

recherche français ou étrangers, des laboratoires

publics ou privés.

The lipoprotein lipase inhibitor ANGPTL3 is negatively

regulated by thyroid hormone

Charlotte Fugier, Jean-Jacques Tousaint, Xavier Prieur, Michelina Plateroti,

Jacques Samarut, Philippe Delerive

To cite this version:

Charlotte Fugier, Jean-Jacques Tousaint, Xavier Prieur, Michelina Plateroti, Jacques Samarut, et

al.. The lipoprotein lipase inhibitor ANGPTL3 is negatively regulated by thyroid hormone. Journal

of Biological Chemistry, American Society for Biochemistry and Molecular Biology, 2006, 281 (17),

pp.11553-11559. �10.1074/jbc.M512554200�. �hal-02666173�

(2)

The Lipoprotein Lipase Inhibitor ANGPTL3 Is Negatively

Regulated by Thyroid Hormone

*

Received for publication, November 23, 2005, and in revised form, January 27, 2006Published, JBC Papers in Press, February 27, 2006, DOI 10.1074/jbc.M512554200

Charlotte Fugier

, Jean-Jacques Tousaint

, Xavier Prieur

, Michelina Plateroti

§

, Jacques Samarut

§

,

and Philippe Delerive

‡1

From

GlaxoSmithKline, Cardiovascular and Urogenital Center of Excellence for Drug Discovery, 25 Avenue du Quebec,

Les Ulis 91951, France and

§

IFR 128, Laboratoire de Biologie Mole´culaire de la Cellule, CNRS UMR 5161, INRA UMR 1237,

Ecole Normale Supe´rieure de Lyon, 46 Alle´e d’Italie, Lyon 69364, France

Whereas the role of thyroid hormone is clearly established in the regulation of cholesterol homeostasis, its involvement in the con-trol of serum triglyceride (TG) levels remains largely debated. Angiopoietin-like proteins 3 and 4 have recently been characterized as potent lipoprotein lipase inhibitors and therefore as important components of plasma triglyceride homeostasis. In the present study, the role of thyroid hormone in the regulation of both

ANGPTL4 and ANGPTL3 gene expression was investigated. In vivo

studies revealed that thyroid hormone down-regulates ANGPTL3 but not ANGPTL4 gene expression in hypothyroid rats. Using thy-roid hormone receptor (TR)-deficient mice, we show that thythy-roid hormone regulates ANGPTL3 gene expression in a TR␤-dependent manner. Transfection studies revealed that this inhibition occurs at the transcriptional level in a DNA binding-independent fashion and requires the proximal (ⴚ171 to ⴙ66) region of the ANGPTL3 gene promoter. Moreover, site-directed mutagenesis experiments indi-cate that the HNF1 site within this proximal region mediates this TR␤-dependent repression. Finally, co-transfection studies and electrophoretic mobility shift assays suggest that TR␤ antagonizes the HNF1␣ signaling pathway by inhibiting its transcriptional activ-ity without interfering with its DNA-binding capacactiv-ity. Taken together, our results lead to the identification of ANGPTL3 as a novel TR␤ target gene and provide a new potential mechanism to explain the hypotriglyceridemic properties of TR␤ agonists in vivo.

Thyroid hormone (T3)2plays major roles in the development and

adult functions of many organs and tissues. Most of the effects of the thyroid hormone are mediated by the thyroid hormone receptors (TRs), which are members of the nuclear receptor superfamily (1). Two dis-tinct genes, THRA and THRB (encoding TR␣ and TR␤, respectively) produce various forms of TR proteins, including the functional recep-tors TR␣1, TR␤1, and TR␤2 (2). Whereas TR isoforms are detectable in almost every tissue, there is some isoform-specific pattern of distribu-tion. TR␣1 is highly expressed in skeletal muscle and brown fat, and TR␣2 expression is mostly restricted to the brain. The almost ubiquitous TR␤1 is mainly expressed in the brain, liver, and kidney, whereas TR␤2 is exclusively present in the pituitary and hypothalamus

in adults. All of the TR isoforms except TR␣2 bind T3 with a similar affinity (2). TRs regulate gene transcription through their binding to specific TR-response elements (TRE) located in the promoter regions of target genes. TRs can bind in the absence of T3 as homodimers but preferentially bind those TRE as heterodimers with another nuclear receptor, namely the retinoid X receptor. TR can positively or negatively regulate T3-responsive gene expression, depending on the nature of the TRE, the hormonal status, and the cellular environment (2). In the absence of T3, the TR/retinoid X receptor heterodimer is associated with corepressors at the TRE. Those corepressors interact with multi-subunit protein complexes containing histone deacetylase (HDAC) activity that maintain the chromatin in a compact state repressing gene activation. Upon T3 binding, TR undergoes a conformational change, releasing corepressors and allowing coactivator binding, thereby pro-moting gene activation through histone acetylation. The transcription of any given gene is defined by the control of the interactions between TR and those co-regulatory proteins (for reviews, see Refs. 3 and 4).

The use of transgenic and knock-out mouse models revealed the existence of TR isoform-specific functions (see Ref. 5 for review). Whereas it has been shown that TR␣ plays a key role in cardiac function by regulating both heart rate and contractility, TR␤ has been character-ized as a master regulator of the hypothalamus-pituitary-thyroid feed-back and an important regulator of cholesterol homeostasis (5). In fact, the link between thyroid disease and lipid disorders has been established several decades ago (6). Hypothyroidism is characterized by elevated low density lipoprotein levels as well as an increased risk of atheroscle-rosis (7, 8). Furthermore, administration of thyroid hormone efficiently lowers plasma cholesterol levels in rodent models and also in humans (9, 10). T3 regulates cholesterol homeostasis by affecting the expression of key hepatic proteins, such as the low density lipoprotein receptor and the cholesterol 7␣-hydroxylase. Using transgenic mice, Gullberg and co-workers (11) have demonstrated that T3 regulates cholesterol home-ostasis in mice in a TR␤-dependent manner. In addition, those authors showed that TR␤ regulates the transcription of CYP7A1, the rate-lim-iting step in bile acid biosynthesis (12). Recently, Johansson et al. (13) demonstrated that TR␤ activation by a synthetic thyromimetic (GC-1) results in a sharp reduction in total cholesterol levels, in agreement with previous findings (14 –16). This strong effect is explained, at least in part, by a stimulation of the reverse cholesterol transport: increase of high density lipoprotein selective uptake in the liver by SR-B1 and a subsequent increase in cholesterol catabolism through Cyp7A activa-tion (13). Interestingly, TR␤ activaactiva-tion by thyromimetics has been shown to lower plasma triglyceride levels in various rodent models (14 – 16). In hypothyroid patients, serum levels of TG-rich lipoprotein were reported to be increased (17). Moreover, Ito et al. (18) showed that administration of T4 to patients with hypothyroidism led to a strong decrease in low density lipoprotein-cholesterol and also triglyceride

lev-*The costs of publication of this article were defrayed in part by the payment of page

charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1To whom correspondence should be addressed: GlaxoSmithKline R&D, CVU CEDD, 25

Ave. du Que´bec, 91951 Les Ulis, France. Tel.: 33-169296081; Fax: 33-169074892; E-mail: pxd14884@gsk.com.

2The abbreviations used are: T3, thyroid hormone; DBD, DNA-binding domain; LPL,

lipoprotein lipase; LXR, liver X receptor; PTU, 6-n-propyl-2-thiouracil; TG, triglyceride; VLDL, very low density lipoprotein; TR, thyroid hormone receptor; TRE, TR-response element(s); HDAC, histone deacetylase; FBS, fetal bovine serum; WT, wild type; PBS, phosphate-buffered saline.

at INRA Institut National de la Recherche Agronomique, on November 8, 2010

www.jbc.org

(3)

els. This decrease was accompanied by a significant increase in lipopro-tein lipase (LPL) activity. In another study, Nikkila and Kekki (19) found that postheparin LPL activity is increased in hyperthyroid state and decreased in hypothyroidism. Finally, Abrams et al. (17) observed that hyperthyroid patients have remarkable facility in clearing VLDL-TG without any significant changes in LPL activity. Altogether, these reports suggest that thyroid hormone influences triglyceride metabo-lism, but the precise molecular mechanism remains to be elucidated.

Recently, novel regulators of LPL activity have been identified. Angio-poietin-like proteins are proteins containing a coiled-coil domain and a fibrinogen-like domain similar to those found in angiopoietins (20). Six members of this growing family have been described so far (for a review, see Ref. 20). In addition to their angiogenic properties in the vasculature, members of this family have been found to play a role in metabolism (20). ANGPTL3 was identified by genetic analysis of the KK/San mice that present low plasma lipid levels despite being hyperinsulinemic and hyperglycemic (21). Administration or overexpression of ANGPTL3 using adenovirus elicited a marked increase in circulating plasma total cholesterol, nonesterified fatty acid levels and TGs (21). ANGPTL3 reg-ulates VLDL-TG levels by inhibiting LPL activity (22). Another study also proposed that ANGPTL3 may be able to target adipocytes to acti-vate lipolysis, thereby enhancing the release of free fatty acids and glyc-erol (23). More recently, a significant genetic association was found between ANGPTL3 and the development of atherosclerosis lesions in both mice and humans (24). The patients carrying the mutated

ANGPTL3allele had higher circulating TG levels (24). Another member of the Angiopoietin-like proteins, ANGPTL4, has also been found to inhibit LPL activity (25). This gene, also called PGAR (peroxisome pro-liferator-activated angiopoietin-related protein) or FIAF (fasting-in-duced adipose factor), is tightly regulated in the liver and in the adipose tissue after feeding and fasting, suggesting a role in fat metabolism (26). Furthermore, transgenic mice overexpressing ANGPTL4 in the heart showed a significant reduction in cardiac LPL activity and a subsequent inhibition in lipoprotein-derived free fatty acid delivery to the heart (27).

In this study, we investigated the potential involvement of thyroid hormone in ANGPTL3 and ANGPTL4 gene regulation. ANGPTL3, but not ANGPTL4, was found to be regulated specifically by TR␤ in vivo. Furthermore, we show that TR␤ negatively regulates this gene by, at least in part, antagonizing the HNF1␣ transcriptional pathway in a DNA binding-independent manner.

EXPERIMENTAL PROCEDURES

Materials—T3 was obtained from Sigma. Charcoal/dextran-treated FBS was from Hyclone. The TR␤-selective agonist GC-1 (16) was pre-pared at GlaxoSmithKline as described (28).

Cell Culture—HepG2 cells (ATCC, Manassas, VA) were maintained in basic Eagle’s medium supplemented with 2 mMglutamine, 1% non-essential amino acids, and 10% (v/v) fetal calf serum in an atmosphere of 5% CO2at 37 °C.

Plasmids—The plasmids pSG5-TR␤ and GAL4-TR␤ (containing the

human TR␤ ligand-binding domain cloned in frame with the DBD of the yeast GAL4 transcription factor) were provided by Dr. J. Moore (GlaxoSmithKline, Research Triangle Park, NC). The pSG5 plasmid was purchased from Stratagene (La Jolla, CA). The G5-Luc reporter vector containing five copies of the GAL4 response element cloned upstream of the minimal thymidine kinase promoter was provided by Promega. The human ANGPTL3 promoter constructs (⫺929 to ⫹109, ⫺296 to ⫹109, ⫺171 to ⫹109, and ⫺66 to ⫹109) were obtained by PCR ampli-fication using human genomic DNA (Clontech) as template. The

result-ing PCR products were inserted as BglII/HindIII fragments into pGL3 basic vector (Promega), yielding⫺929 to ⫹109, ⫺296 to ⫹109, ⫺171 to ⫹109, and ⫺66 to ⫹109 ANGPTL3-Luc. The mutation of the LXR and HNF1 binding sites within the⫺929 to ⫹109 ANGPTL3 promoter were obtained by site-directed mutagenesis (Stratagene, La Jolla, CA). The GAL4-HNF1␣ construct was obtained by PCR amplification of full-length HNF1␣ using a human liver cDNA library (Clontech) as tem-plate. The resulting PCR fragment was cloned in frame with the GAL4 DNA-binding domain into the pM vector (Clontech), yielding GAL4-HNF1␣. All constructs were verified by DNA sequence analysis.

Transient Transfection Assays—HepG2 cells, plated in 96-well plates at 50 – 60% confluence in basic Eagle’s medium supplemented with 10% fetal calf serum, were transiently transfected with reporter and receptor expression plasmids using Fugene 6 reagent (Roche Applied Science) as indicated in the legends for Figs. 3–7. The pSEAP2 expression plasmid (Clontech) was cotransfected to assess transfection efficiency. 24 h post-transfection, cells were refed with fresh medium containing 1% char-coal/dextran-treated serum and TR ligands or vehicle (Me2SO or 0.1%

ethanol). 24 h later, cells were collected and assayed for luciferase and alkaline phosphatase activities. All experiments were repeated at least three times. Results are expressed as mean⫾ S.E.

Animal Studies—Experimental protocols were approved by the GlaxoSmithKline Institutional Animal Care and Use Committee. Male Wistar rats (12 weeks old) were obtained from Charles River Laborato-ries. Hypothyroidism was induced by administration by gavage of a 10-mg/kg/day 6-n-propyl-2-thiouracil (PTU) aqueous solution (Sigma) for 3 weeks. On the last day of the treatment, half of the PTU-treated rats received an intraperitoneal injection of L-T3 (300␮g/kg in 100 ␮l of PBS). 6 h postinjection, animals were sacrificed, and livers were excised for RNA preparation. Adult 8 –10-week-old males TR␣0/0 (29) and

TR␤⫺/⫺(30) as well as wild type (WT) mice were used. Mice were

housed and maintained with approval from the animal experimental committee of the Ecole Normale Supe´rieure de Lyon (Lyon, France). Briefly, for each genotype, control animals were fed standard mouse chow. TH deficiency was induced by feeding a low iodine diet supple-mented with 0.15% PTU purchased from Harlan/Teklad and 0.05% methimazole into the drinking water. The day before the sacrifice (5 pm), one-half of the PTU-treated mice received an intraperitoneal injection of T3 (300␮g/kg in 100 ␮l of PBS). The PTU- and TH-treated mice were sacrificed at the end of the night cycle after an overnight fasting. At the conclusion of each experiment, blood was recovered for serum preparation, and the liver was quickly removed, frozen in liquid nitrogen, and used for RNA extraction.

RNA Analysis—Total RNA was extracted using TRIZOL reagent (Invitrogen) following the manufacturer’s instructions. The RNA was treated with DNase I (Ambion Inc., Austin, TX) at 37 °C for 30 min, followed by inactivation at 75 °C for 5 min. Real time quantitative PCR assays were performed using an Applied Biosystems 7900 sequence detector. Total RNA (1␮g) was reverse transcribed with random hex-amers using a Taqman reverse transcription reagent kit (Applied Bio-systems) following the manufacturer’s protocol. RNA expression levels were determined by Sybr green assays as described (31).␤-Actin tran-script was used as an internal control to normalize the variations for RNA amounts. Gene expression levels are expressed relative to␤-actin mRNA levels. All of the PCR primers used in the present study are available upon request.

Electrophoretic Mobility Shift Assay—Double-stranded oligonucleotides (5⬘- GCTTAATGATTAACT-3⬘) were end-labeled with [␥-32P]ATP using

T4 polynucleotide kinase according to standard procedures. Nuclear extracts were prepared as described (32, 33), and protein concentration

TR

␤ Down-regulates ANGPTL3 Expression

at INRA Institut National de la Recherche Agronomique, on November 8, 2010

www.jbc.org

(4)

was determined using the BCA kit (Bio-Rad). 5␮g of extracts were incubated with 100,000 cpm of labeled probe for 30 min at room tem-perature in 20␮l of buffer containing 10 mMTris (pH 7.5), 50 mMNaCl, 1 mMdithiothreitol, 1 mMEDTA, 5% glycerol, 0.3␮g bovine serum albumin, and 2␮g of poly(dI-dC). DNA-protein complexes were ana-lyzed by electrophoresis in a 5% nondenaturing polyacrylamide gel with 0.5⫻ TBE buffer. The gel was then dried and exposed at ⫺80 °C for autoradiography.

RESULTS AND DISCUSSION

In order to study a potential involvement of thyroid hormone in

ANGPTL3and ANGPTL4 gene regulation, male Wistar rats were ren-dered hypothyroid using a 3-week PTU treatment. This treatment induced a dramatic fall in both T4 and T3 levels. Animals then received T3 by intraperitoneal injection or vehicle (PBS). Hepatic gene expres-sion was monitored 6 h later by real time quantitative PCR (Fig. 1). As expected, T3 injection resulted in a significant induction of SPOT14 gene expression (3.5-fold) in the hypothyroid rats in agreement with previous reports (34). Interestingly, ANGPTL3, but not ANGPTL4, gene expression was markedly down-regulated by the treatment (⫺70%), suggesting a role for thyroid hormone in the control of ANGPTL3 expression in vivo.

To determine which TR isotype mediates this effect, we next meas-ured ANGPTL3 gene expression in WT, TR␣ KO, and TR␤ KO mice that had been subjected to PTU treatment for 3 weeks. At the end of this treatment, hypothyroid mice received T3 (300␮g/kg) by intraperitoneal injection. 16 h later, mice were sacrificed, and hepatic gene expressions were monitored by Sybrman analysis (Fig. 2). As expected, SPOT14 was strongly (60-fold) induced in WT and TR␣ KO mice, but not in TR␤ KO mice (Fig. 2A), which is consistent with previous reports (34).

ANGPTL3mRNA levels were significantly diminished after T3

injec-tions in both WT and TR␣ KO mice. By contrast, this repressive effect of T3 on ANGPTL3 expression was not observed in TR␤-deficient animals (Fig. 2B). Finally, as a control, liver ANGPTL4 mRNA levels were not significantly affected by T3 injection (Fig. 2C). Taken together, these results demonstrate that ANGPTL3 is negatively regulated by T3 in vivo in a TR␤-dependent manner.

In order to understand by which mechanism TR␤ regulates

ANGPTL3gene expression, a 1-kb fragment of the promoter was cloned upstream of the luciferase gene. A functional analysis of this promoter was then carried out in HepG2 cells (Fig. 3). Preliminary experiments revealed that HepG2 cells express extremely low TR␤ levels, as demon-strated by Taqman analysis (data not shown) and in line with previous reports (35, 36). In the absence of co-transfected TR␤, treatment with T3 or thyromimetics (GC-1 and CGS-23425) did not significantly affect

ANGPTL3promoter activity (Fig. 3A). Co-transfection of TR␤ in the

absence of ligand resulted in a small but significant inhibition of the reporter gene activity. This effect was potentiated by the addition of the different agonists, resulting in a 10-fold repression of the promoter activity (Fig. 3A). Furthermore, this ligand-induced transcriptional inhi-bition was dose-dependent, as demonstrated on Fig. 3B. This inhiinhi-bition is also specific, since co-transfection of another nuclear receptor, per-oxisome proliferator-activated receptor␣, in the presence or absence of its synthetic ligand, failed to suppress ANGPTL3 promoter activity (data not shown). Taken together, the results indicate that T3 regulates ANGTPL3 at the transcriptional level. Since T3 has also been shown to regulate gene expression via mRNA destabilization (37), mRNA half-life studies were performed in rat primary hepatocytes treated with actino-mycin D in the presence of T3 (100 nM) or vehicle. In those experiments, T3 did not affect ANGPTL3 mRNA half-life (around 20 h) (data not shown), indicating again that T3 regulates ANGPTL3 gene expression at the transcriptional level.

To determine whether T3-mediated ANGPTL3 promoter repression requires TR␤ DNA binding, we next evaluated the influence of a TR␤ construct lacking the DBD on ANGPTL3 promoter activity. Co-trans-fection of increasing concentrations of TR␤ ligand-binding domain construct resulted in a dose-dependent inhibition of the ANGPTL3 pro-moter (Fig. 4B). This inhibition was further augmented by the addition of T3 similarly as reported for the full-length receptor (Fig. 4A). This finding strongly suggests that TR␤ negatively regulates ANGPTL3 pro-moter activity in a DNA binding-independent manner.

To localize which ANGPTL3 promoter region confers TR␤ respon-siveness, 5⬘ deletions of the promoter were transiently transfected into HepG2 cells. As a control, co-transfection of TR␤ resulted in a ligand-dependent inhibition of the 1-kb promoter construct as previously shown (Figs. 3 and 4). The⫺296 to ⫹109 and ⫺171 to ⫹109 promoter

FIGURE 1. T3 inhibits ANGPTL3 expression in adult hypothyroid rats. Adult male rats (4 animals/group) were rendered hypothyroid by PTU treatment for 3 weeks. On the last day of the treatment, one-half of the PTU treated rats received an intraperitoneal

injec-tion of T3 (300␮g/kg in 100 ␮l of PBS). 6 h postinjection, total liver RNA was extracted,

and gene expression levels were measured by real time quantitative PCR. Data are

mean⫾ S.E. of four individual animals. (*, p ⬍ 0.05 versus PTU-treated animals).

FIGURE 2. Thyroid hormone regulates ANGPTL3 gene expression in vivo in a TR␤-dependent manner. Hypothyroid WT, TR␣ KO, and TR␤ KO mice (4 animals/group) that received

PTU plus methimazole for 3 weeks were injected intraperitoneally with L-T3 (300␮g/kg) or vehicle (PBS). 16 h postinjection, total liver RNA was extracted, and gene expression levels

were measured by real time quantitative PCR. Data are mean⫾ S.E. of four individual animals. *, p ⬍ 0.05 versus PTU-treated animals.

at INRA Institut National de la Recherche Agronomique, on November 8, 2010

www.jbc.org

(5)

constructs were also strongly inhibited by the T3 addition when TR␤ was co-transfected (Fig. 5). By contrast, the⫺66 to ⫹109 promoter activity was not repressed by the liganded TR␤ (Fig. 5), indicating that the⫺171 to ⫹66 promoter region confers TR␤ responsiveness. A bioin-formatic analysis revealed the presence of putative LXR and HNF1 binding sites within this region, in agreement with a previous report

(38). Since TR␤ represses ANGPTL3 promoter activity in a DNA bind-ing-independent manner, we hypothesized that liganded TR␤ could inhibit the transcription via a trans-repression mechanism. Therefore, both binding sites were mutated by site-directed mutagenesis, and the resulting promoter constructs were tested in HepG2 cells. The con-struct bearing the LXR binding site mutation was significantly inhibited by T3 treatment in TR␤-expressing HepG2 cells similarly as described for the wild type promoter (Fig. 6). By contrast, mutation of the HNF1 site completely abolished TR␤-mediated promoter repression (Fig. 6), indicating that this site is required for TR␤-mediated ANGPTL3 pro-moter regulation. Of note, this construct has a significant lower basal promoter activity compared with the WT promoter, which is consis-tent with HNF1 playing a role in ANGPTL3 gene regulation (data not shown).

Next, we investigated the molecular basis of this cross-talk between TR␤ and the HNF1 signaling. First, we tested whether TR␤ could repress HNF1␣ transcriptional activity independently of the promoter context. Therefore, the effect of TR␤ activation was analyzed on a GAL4-dependent reporter, activated by a GAL4-HNF1␣ chimera. Co-transfection of the GAL4-HNF1␣ chimera resulted in a strong transcriptional activation (170-fold), which was significantly (⫺70%) inhibited by TR␤ co-transfection in a ligand-dependent manner (Fig. 7A). This result suggests that TR␤ can repress HNF1-driven transcription independently of the promoter context. As a control, TR␤activationdidnotinfluencetheactivityoftheGAL4DBD alone (Fig. 7A), and co-transfection of peroxisome proliferator-activated receptor␣ did not affect HNF1-driven promoter activity, demonstrating the specificity of the observed effects (data not shown). We then assessed

FIGURE 3. TR␤ activation leads to ANGPTL3 promoter repression in HepG2 cells. A, HepG2 cells were transfected with the human ANGPTL3 promoter (⫺929 to ⫹109

ANGPTL3-Luc; 40 ng) in the presence of TR␤ or empty vector (pSG5; 10 ng). 24 h later, cells were refed with fresh medium supplemented with 1% charcoal/dextran-treated FBS and various TR

agonists (100 nM) or vehicle (Me2SO (DMSO), 0.1%) for an additional 24 h. B, HepG2 cells were transfected with the human ANGPTL3 promoter (⫺929 to ⫹109 ANGPTL3-Luc; 40 ng) in

the presence of TR␤ or empty vector (pSG5; 10 ng). 24 h later, cells were refed with fresh medium supplemented with 1% charcoal/dextran-treated FBS and increasing concentrations

of T3 or vehicle (0.1% ethanol) for an additional 24 h. Results are plotted as repression levels.

FIGURE 4. TR␤ represses ANGPTL3 promoter

activity in a DNA binding-independent man-ner. HepG2 cells were transfected with the human

ANGPTL3 promoter (⫺929 to ⫹109 ANGPTL3-Luc;

40 ng) in the presence of increasing concentra-tions of pGS5-TR␤ (A) or GAL4-TR␤ (B) or empty vector (pSG5 and GAL4, respectively). 24 h later, cells were refed with fresh medium supple-mented with 1% charcoal/dextran-treated FBS in

the presence of T3 (100 nM) or vehicle (ethanol

0.1%) for an additional 24 h. Results are plotted as repression levels.

FIGURE 5. Theⴚ171 to ⴙ66 region of the ANGPTL3 promoter confers TR␤

respon-siveness. HepG2 cells were transfected with various 5⬘-deletions of the human ANGPTL3

promoter (40 ng) and TR␤ or empty vector (pSG5; 10 ng). 24 h later, cells were refed with fresh medium supplemented with 1% charcoal/dextran-treated FBS in the presence of

T3 (100 nM) or vehicle (ethanol 0.1%) for an additional 24 h. Results are plotted as

repres-sion levels. *, p⬍ 0.05.

TR

␤ Down-regulates ANGPTL3 Expression

at INRA Institut National de la Recherche Agronomique, on November 8, 2010

www.jbc.org

(6)

whether TR␤ activation resulted in a loss of HNF1␣ DNA binding using electrophoretic mobility shift assays. In a first set of experiments, we verified that HNF1 was binding to the predicted site we identified in ANGPTL3 promoter. Incubation of HepG2 nuclear extracts with this32P-radiolabeled

oligonucleotide containing the HNF1 site resulted in a strong protein-DNA complex, which was significantly reduced by a preincubation with a poly-clonal HNF1␣ antibody (Fig. 7B). HNF1␣ binding to this site was subse-quently examined in HepG2 cells transfected with TR␤ or empty vector (pSG5). In pSG5- or TR␤-transfected cells, HNF1␣ DNA binding was not modified by T3 treatment (Fig. 7B), suggesting that TR␤ does not repress HNF1␣ transcriptional activity by preventing its DNA binding.

In the present study, we have shown that T3 down-regulates

ANGPTL3but not ANGPTL4 gene expression in vivo in a

TR␤-depend-ent manner. The role of the␤ isotype is not surprising, since it is the prevalent TR in the liver, representing 85% of the T3-binding activity (39). Using promoter mapping experiments, a region conferring T3 responsiveness was identified within the proximal promoter. Interest-ingly, this region contains an LXR response element, a DNA-binding site that can be shared by TR␤ (40). Recently, two groups suggested that unliganded TR represses LXR activation on an LXR response element

by competing for the same binding site (41, 42). In this study, TR␤ was found to inhibit ANGPTL3 promoter activity in a strictly ligand-de-pendent manner (Fig. 3). Furthermore, this inhibition occurs in a DNA binding-independent fashion (Fig. 4B). Finally, a construct mutated for the LXR response element was repressed by co-transfection of TR␤ in the presence of T3 (Fig. 6). Altogether, those results strongly suggest that TR␤ down-regulates ANGPTL3 gene expression in a LXR-inde-pendent manner.

This proximal promoter region contains also an HNF1 binding site whose presence is required for TR␤ to mediate this transcriptional repres-sion. Transfection studies and electrophoretic mobility shift assays suggest that TR␤ can antagonize HNF1␣ transcriptional activity independently of the promoter context without interfering with its DNA-binding capacity. Interestingly, Caturla et al. (43) suggested that T3 down-regulates the mouse␣-foetoprotein promoter activity by competing for DNA binding with HNF1 and CCAAT/enhancer-binding proteins. Several hypotheses could be made to explain how TR␤ affects HNF1␣-driven transcription. First, TR␤ could be recruited to the negatively regulated gene via an inter-action with HNF1␣, thereby preventing the recruitment of coactivator(s) and/or allowing the binding of co-repressor(s), similar to what has been described for the AP-1/TR cross-talk (44, 45). However, co-immunopre-cipitation experiments did not allow us to detect any significant association between HNF1␣ and TR␤ (data not shown). In addition, electrophoretic mobility shift assays did not reveal any interference of HNF1 DNA binding in the presence of co-transfected TR␤ (Fig. 7B). Moreover, TR␤ does not repress all of the HNF1-driven gene expression, indicating some gene-spe-cific mechanism. Altogether, these data strongly argue against a direct HNF1-TR␤ interaction. It has been shown that TR␤ is able to recruit co-repressors and HDAC activity on certain gene promoters. For instance, TR␤ has been shown to recruit histone deacetylase in a ligand-dependent fashion on the thyrotropin␤ gene (46). We tested a potential implication of HDAC in ANGPTL3 gene regulation. Whereas the potent HDAC inhibi-tor, trichostatin A, increased ANGPTL3 promoter activity in a dose-dependent manner, it did not prevent TR␤-mediated transcriptional repression (data not shown), ruling out a potential involvement of HDACs in this transcriptional cross-talk. However, TR␤ could sequester a limiting co-activator or co-repressor specifically recruited by HNF1␣ on the

ANGPTL3promoter. This is the so-called squelching model (47, 48). The identification of such factor(s) will require further experiments.

The central role of T3 in cholesterol homeostasis is well docu-mented (6). By contrast, its involvement in the regulation of serum TG levels remains largely debated. Nevertheless, a recent study

FIGURE 6. The HNF1 site within the ANGPTL3 promoter is required for TR

␤-depend-ent repression. HepG2 cells were transfected with wild type or LXR response elem␤-depend-ent-

element-mutated or HNF1 response element-element-mutated promoter construct (40 ng) and TR␤ or

empty vector (pSG5; 10 ng). 24 h later, cells were refed with fresh medium supplemented

with 1% charcoal/dextran-treated FBS in the presence of T3 (100 nM) or vehicle (ethanol

0.1%) for an additional 24 h. Results are plotted as repression levels. *, p⬍ 0.05.

FIGURE 7. TR␤ antagonizes HNF1␣

transcrip-tional activity without interfering with its DNA binding. A, HepG2 cells were transfected with

G5-Luc (40 ng), GAL4-HNF1␣ (5 ng), and TR␤ (5 ng) or empty vectors (GAL4 DBD and pSG5, respec-tively). 24 h later, cells were refed with fresh medium supplemented with 1%

charcoal/dex-tran-treated FBS in the presence of T3 (100 nM) or

vehicle (0.1% ethanol) for an additional 24 h. B, 5 ␮g of nuclear extracts prepared from HepG2 cells transfected with pSG5 or TR␤ and treated for 24 h

with T3 (100 nM) or vehicle (0.1% ethanol) were

subjected to electrophoretic mobility shift assay using the HNF1 site radiolabeled probe. Shifted DNA-protein complexes were visualized by auto-radiography. The HNF1-DNA complex was signifi-cantly reduced by incubating HepG2 nuclear

extracts with 1␮l of HNF1␣ antibody for 10 min.

N.E., nuclear extracts.

at INRA Institut National de la Recherche Agronomique, on November 8, 2010

www.jbc.org

(7)

showed that administration of a TR␤-selective agonist results in a strong decrease of VLDL-TG in rodent models (13). These authors suggested that TR␤ activation leads to SREBP1c gene suppression, thereby inhibiting hepatic fatty acid and TG synthesis (13). Tran-scriptome analysis comparing TR␤ KO versus wild type mice revealed that T3-mediated fatty acid synthase and stearoyl-CoA desaturase gene regulation was rapid and transient (34). In this study, we were able to identify ANGPTL3 as a novel target gene for T3 in vivo. ANGPTL3 is a hepatic secreted protein with structural similarity to angiopoietins (50). ANGPTL3 was identified by genetic analysis of the KK/San mice that present low plasma lipid levels despite being hyperinsulinemic and hyperglycemic (21). Adminis-tration or overexpression of ANGPTL3 using adenovirus elicited a marked increase in circulating plasma total cholesterol, nonesteri-fied fatty acid levels, and TGs (21). ANGPTL3 regulates VLDL-TG levels by inhibiting LPL activity (22). Another study also proposed that ANGPTL3 may be able to target the adipocytes and to activate lipolysis, thereby enhancing the release of free fatty acids and glyc-erol (23). More recently, a significant genetic association was found between ANGPTL3 and the development of atherosclerosis lesions in both mice and humans (24). The patients carrying the mutated

ANGPTL3 allele had higher circulating TG levels (24). Another member of the angiopoietin-like proteins, ANGPTL4, has also been found to inhibit LPL activity (25). In this study, we found that T3 regulates ANGPTL3 but not ANGPTL4 gene expression in rats and also in mice (Fig. 1 and 2). Since ANGPTL3 behaves as an LPL inhib-itor, it is tempting to speculate that T3 and its synthetic analogues lower plasma TG levels by suppressing ANGPTL3 expression, thereby activating plasma LPL activity. Moreover, recent studies suggested that apolipoprotein A-5, which accelerates VLDL-TG hydrolysis via LPL activation (51, 52), was up-regulated by T3- or TR␤-selective molecules in vitro and also in vivo (53). Altogether, these results suggest that T3 may increase LPL activity by different mechanisms, thereby resulting in a sharp reduction in plasma TG. To determine the biological relevance of T3-mediated ANGPTL3 regulation, it would be interesting to administer a TR␤ agonist to

ANGPTL3-deficient mice and to measure TG levels during this experiment. However, ANGPTL3-deficient mice display already an increased LPL activity (9-fold higher compared with wild type ani-mals) and also a severe hypotriglyceridemia in the fed state (49). Therefore, it will be difficult to assess the TG-lowering activity of TR␤ agonist in such animal models.

In conclusion, this study led to the identification of ANGPTL3 as a negatively regulated gene by T3 in vivo. In addition to its central role in cholesterol homeostasis, TR␤ seems to regulate an array of proteins involved in TG metabolism. Therefore, compounds targeting this receptor and devoid of the deleterious effects of T3 may be useful ther-apeutic agents for the treatment of lipid disorders and obesity.

Acknowledgments—We thank Dr. Ste´phane Huet (GlaxoSmithKline Car-diovascular and Urogenital Center of Excellence for Drug Discovery) for critical reading of the manuscript. We gratefully acknowledge Nadine Agu-ilera for animal handling at the animal facility of the Ecole Normale Supe´rieure de Lyon.

REFERENCES

1. Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schutz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., and Evans, R. M. (1995) Cell 83, 835– 839

2. Lazar, M. A. (1993) Endocr. Rev. 14, 184 –193

3. Moore, J. M., and Guy, R. K. (2005) Mol. Cell Proteomics 4, 475– 482

4. Wu, Y., and Koenig, R. J. (2000) Trends Endocrinol. Metab. 11, 207–211 5. Flamant, F., and Samarut, J. (2003) Trends Endocrinol. Metab. 14, 85–90 6. Duntas, L. H. (2002) Thyroid 12, 287–293

7. Hansson, P., Valdemarsson, S., and Nilsson-Ehle, P. (1983) Horm. Metab. Res. 15, 449 – 452

8. Roberts, C. G., and Ladenson, P. W. (2004) Lancet 363, 793– 803

9. Aviram, M., Luboshitzky, R., and Brook, J. G. (1982) Clin. Biochem. 15, 62– 66 10. Engelken, S. F., and Eaton, R. P. (1981) Atherosclerosis 38, 177–188

11. Gullberg, H., Rudling, M., Salto, C., Forrest, D., Angelin, B., and Vennstrom, B. (2002)

Mol. Endocrinol. 16,1767–1777

12. Gullberg, H., Rudling, M., Forrest, D., Angelin, B., and Vennstrom, B. (2000) Mol.

Endocrinol. 14,1739 –1749

13. Johansson, L., Rudling, M., Scanlan, T. S., Lundasen, T., Webb, P., Baxter, J., Angelin, B., and Parini, P. (2005) Proc. Natl. Acad. Sci. U. S. A. 102, 10297–10302

14. Ness, G. C., Lopez, D., Chambers, C. M., Newsome, W. P., Cornelius, P., Long, C. A., and Harwood, H. J., Jr. (1998) Biochem. Pharmacol. 56, 121–129

15. Taylor, A. H., Stephan, Z. F., Steele, R. E., and Wong, N. C. (1997) Mol. Pharmacol. 52, 542–547

16. Trost, S. U., Swanson, E., Gloss, B., Wang-Iverson, D. B., Zhang, H., Volodarsky, T., Grover, G. J., Baxter, J. D., Chiellini, G., Scanlan, T. S., and Dillmann, W. H. (2000)

Endocrinology 141,3057–3064

17. Abrams, J. J., Grundy, S. M., and Ginsberg, H. (1981) J. Lipid Res. 22, 307–322 18. Ito, M., Takamatsu, J., Matsuo, T., Kameoka, K., Kubota, S., Fukata, S., Tamai, H.,

Miyauchi, A., Kuma, K., and Hanafusa, T. (2003) Clin. Endocrinol. (Oxf) 58, 621– 626 19. Nikkila, E. A., and Kekki, M. (1972) J. Clin. Invest. 51, 2103–2114

20. Oike, Y., Akao, M., Kubota, Y., and Suda, T. (2005) Trends Mol. Med.

21. Koishi, R., Ando, Y., Ono, M., Shimamura, M., Yasumo, H., Fujiwara, T., Horikoshi, H., and Furukawa, H. (2002) Nat. Genet. 30, 151–157

22. Shimizugawa, T., Ono, M., Shimamura, M., Yoshida, K., Ando, Y., Koishi, R., Ueda, K., Inaba, T., Minekura, H., Kohama, T., and Furukawa, H. (2002) J. Biol. Chem. 277, 33742–33748

23. Shimamura, M., Matsuda, M., Kobayashi, S., Ando, Y., Ono, M., Koishi, R., Furukawa, H., Makishima, M., and Shimomura, I. (2003) Biochem. Biophys. Res. Commun. 301, 604 – 609

24. Korstanje, R., Eriksson, P., Samnegard, A., Olsson, P. G., Forsman-Semb, K., Sen, S., Churchill, G. A., Rollins, J., Harris, S., Hamsten, A., and Paigen, B. (2004)

Atheroscle-rosis 177,443– 450

25. Yoshida, K., Shimizugawa, T., Ono, M., and Furukawa, H. (2002) J. Lipid Res. 43, 1770 –1772

26. Kersten, S., Mandard, S., Tan, N. S., Escher, P., Metzger, D., Chambon, P., Gonzalez, F. J., Desvergne, B., and Wahli, W. (2000) J. Biol. Chem. 275, 28488 –28493 27. Yu, X., Burgess, S. C., Ge, H., Wong, K. K., Nassem, R. H., Garry, D. J., Sherry, A. D.,

Malloy, C. R., Berger, J. P., and Li, C. (2005) Proc. Natl. Acad. Sci. U. S. A. 102, 1767–1772

28. Chiellini, G., Apriletti, J. W., Yoshihara, H. A., Baxter, J. D., Ribeiro, R. C., and Scanlan, T. S. (1998) Chem. Biol. 5, 299 –306

29. Gauthier, K., Plateroti, M., Harvey, C. B., Williams, G. R., Weiss, R. E., Refetoff, S., Willott, J. F., Sundin, V., Roux, J. P., Malaval, L., Hara, M., Samarut, J., and Chassande, O. (2001) Mol. Cell. Biol. 21, 4748 – 4760

30. Gauthier, K., Chassande, O., Plateroti, M., Roux, J. P., Legrand, C., Pain, B., Rousset, B., Weiss, R., Trouillas, J., and Samarut, J. (1999) EMBO J. 18, 623– 631

31. Delerive, P., Galardi, C. M., Bisi, J. E., Nicodeme, E., and Goodwin, B. (2004) Mol.

Endocrinol. 18,2378 –2387

32. Dignam, J. D., Martin, P. L., Shastry, B. S., and Roeder, R. G. (1983) Methods Enzymol.

101,582–598

33. Dignam, D. R. (1983) Healthc. Financ. Manage. 37, 38 – 40

34. Flores-Morales, A., Gullberg, H., Fernandez, L., Stahlberg, N., Lee, N. H., Vennstrom, B., and Norstedt, G. (2002) Mol. Endocrinol. 16, 1257–1268

35. Shin, D. J., and Osborne, T. F. (2003) J. Biol. Chem. 278, 34114 –34118

36. Xiong, S., Chirala, S. S., Hsu, M. H., and Wakil, S. J. (1998) Proc. Natl. Acad. Sci.

U. S. A. 95,12260 –12265

37. Staton, J. M., and Leedman, P. J. (1998) Endocrinology 139, 1093–1100

38. Kaplan, R., Zhang, T., Hernandez, M., Gan, F. X., Wright, S. D., Waters, M. G., and Cai, T. Q. (2003) J. Lipid Res. 44, 136 –143

39. Weiss, R. E., Murata, Y., Cua, K., Hayashi, Y., Seo, H., and Refetoff, S. (1998)

Endocri-nology 139,4945– 4952

40. Chawla, A., Repa, J. J., Evans, R. M., and Mangelsdorf, D. J. (2001) Science 294, 1866 –1870

41. Hashimoto, K., Cohen, R. N., Yamada, M., Markan, K. R., Monden, T., Satoh, T., Mori, M., and Wondisford, F. E. (2005) J. Biol. Chem. 281, 295–302

42. Kawai, K., Sasaki, S., Morita, H., Ito, T., Suzuki, S., Misawa, H., and Nakamura, H. (2004) Endocrinology 145, 5515–5524

43. Caturla, M., Van Reeth, T., Dreze, P., Szpirer, J., and Szpirer, C. (1997) Mol. Cell.

Endocrinol. 135,139 –145

TR

␤ Down-regulates ANGPTL3 Expression

at INRA Institut National de la Recherche Agronomique, on November 8, 2010

www.jbc.org

(8)

44. Pfahl, M. (1993) Endocr. Rev. 14, 651– 658

45. Rogatsky, I., Zarember, K. A., and Yamamoto, K. R. (2001) EMBO J. 20, 6071– 6083 46. Sasaki, S., Lesoon-Wood, L. A., Dey, A., Kuwata, T., Weintraub, B. D., Humphrey, G., Yang, W. M., Seto, E., Yen, P. M., Howard, B. H., and Ozato, K. (1999) EMBO J. 18, 5389 –5398

47. Kamei, Y., Xu, L., Heinzel, T., Torchia, J., Kurokawa, R., Gloss, B., Lin, S. C., Heyman, R. A., Rose, D. W., Glass, C. K., and Rosenfeld, M. G. (1996) Cell 85, 403– 414 48. Tagami, T., Madison, L. D., Nagaya, T., and Jameson, J. L. (1997) Mol. Cell. Biol. 17,

2642–2648

49. Koster, A., Chao, Y. B., Mosior, M., Ford, A., Gonzalez-Dewhitt, P. A., Hale, J. E., Li, D., Qiu, Y., Fraser, C. C., Yang, D. D., Heuer, J. G., Jaskunas, S. R., and Eacho, P. (2005)

Endocrinology 146,4943– 4950

50. Conklin, D., Gilbertson, D., Taft, D. W., Maurer, M. F., Whitmore, T. E., Smith, D. L., Walker, K. M., Chen, L. H., Wattler, S., Nehls, M., and Lewis, K. B. (1999) Genomics

62,477– 482

51. Fruchart-Najib, J., Bauge, E., Niculescu, L. S., Pham, T., Thomas, B., Rommens, C., Majd, Z., Brewer, B., Pennacchio, L. A., and Fruchart, J. C. (2004) Biochem. Biophys.

Res. Commun. 319,397– 404

52. Merkel, M., Loeffler, B., Kluger, M., Fabig, N., Geppert, G., Pennacchio, L. A., Laatsch, A., and Heeren, J. (2005) J. Biol. Chem. 280, 21553–21560

53. Prieur, X., Huby, T., Coste, H., Schaap, F. G., Chapman, M. J., and Rodriguez, J. C. (2005) J. Biol. Chem. 280, 27533–27543

at INRA Institut National de la Recherche Agronomique, on November 8, 2010

www.jbc.org

Références

Documents relatifs

Le taux d’emploi des travailleurs handicapés en 2009, rapport du nombre de bénéficiaires en équivalent-temps plein et de l’effectif d’assujettis- sement de l’ensemble

Utlisez la droite gradu´ ee pour calculer chaque diff´

Elle a prouvé que dans cette zone des pratiques agroécologiques de conservation des eaux et des sols sont importantes pour le maintien et la fertilité des sols agricoles et

Therefore, the aim of this prospective follow-up study was to investigate the long-term outcome with respect to esthetic appearance, scar quality, and wrist function as well as

اشل ؽيبتي جئاتشلا للاخ ؽم ونأب لا ؽيسمعسلا ؽم رؾكحلاو ثانلاا تاىاجتا يف قوخف ججؾت ,ؽييداعلا لا ذشجلا نا يا خثؤي يسيداكلاا جمجلا ؾحن

In 2003, Fritz Graf critically inves- tigated the initiatory character of mysteries (which is the descriptive focus of Jan N. Bremmer’s Initiation into the Mysteries in Ancient

Overpressures, propagation rates and ignition delays are presented in Figures 10–12, respectively, as functions of initial pressures for the 90-10 propellant and the two studied

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des